[HTML][HTML] Repurposing drugs in oncology: next steps
C Verbaanderd, L Meheus, I Huys, P Pantziarka - Trends in cancer, 2017 - cell.com
The repurposing of existing non-cancer drugs is a potential source of new treatment options
for cancer patients with high unmet medical needs. While scientific research is progressing …
for cancer patients with high unmet medical needs. While scientific research is progressing …
[HTML][HTML] Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
P Pantziarka, G Bouche, L Meheus… - …, 2014 - ncbi.nlm.nih.gov
Cimetidine, the first H 2 receptor antagonist in widespread clinical use, has anti-cancer
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …
[HTML][HTML] Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
…, MB Schaaf, VP Sukhatme, P Pantziarka… - …, 2017 - ncbi.nlm.nih.gov
Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline
antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the …
antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the …
Repurposing drugs in oncology: From candidate selection to clinical adoption
P Pantziarka, C Verbaanderd, I Huys, G Bouche… - Seminars in Cancer …, 2021 - Elsevier
Drug repurposing is a strategy that aims to develop novel cancer treatments through the
reuse of existing medicines developed in other disease areas. Such a strategy includes the …
reuse of existing medicines developed in other disease areas. Such a strategy includes the …
[HTML][HTML] Repurposing infectious diseases vaccines against cancer
L Vandeborne, P Pantziarka, AMT Van Nuffel… - Frontiers in …, 2021 - frontiersin.org
Vaccines used to prevent infections have long been known to stimulate immune responses
to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to …
to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to …
[HTML][HTML] Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
P Pantziarka, V Sukhatme, G Bouche… - …, 2016 - ncbi.nlm.nih.gov
Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug
(NSAID), with a range of actions which are of interest in an oncological context. While there …
(NSAID), with a range of actions which are of interest in an oncological context. While there …
[HTML][HTML] Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
P Pantziarka, G Bouche, L Meheus… - …, 2014 - ncbi.nlm.nih.gov
Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer
properties that have been elucidated in a broad range of pre-clinical studies across a …
properties that have been elucidated in a broad range of pre-clinical studies across a …
[HTML][HTML] Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
P Pantziarka, G Bouche, V Sukhatme… - …, 2016 - ncbi.nlm.nih.gov
Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor
antagonist (beta-blocker), with a range of actions which are of interest in an oncological …
antagonist (beta-blocker), with a range of actions which are of interest in an oncological …
[HTML][HTML] ReDO_DB: the repurposing drugs in oncology database
P Pantziarka, C Verbaanderd, V Sukhatme… - …, 2018 - ncbi.nlm.nih.gov
Repurposing is a drug development strategy that seeks to use existing medications for new
indications. In oncology, there is an increased level of activity looking at the use of non …
indications. In oncology, there is an increased level of activity looking at the use of non …
[HTML][HTML] Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
P Pantziarka, V Sukhatme, G Bouche… - …, 2015 - ncbi.nlm.nih.gov
Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of
clinical activity that is of interest in oncology. There is evidence that at the clinically relevant …
clinical activity that is of interest in oncology. There is evidence that at the clinically relevant …